- SPH Sine will use Marinomed's proprietary Marinosolv technology to dissolve its active pharmaceutical ingredient (API) in an orally inhaled and nasal drug product (OINDP) formulation
- The developed know-how technology of the unique formulated product will be protected via patent filing
- Significant growth potential on the dynamic Chinese healthcare market
The full press release is available here: